Biography

Prof. William J. Murphy

University of California, USA

Professor and Vice-Chair for Research


Email: wmjmurphy@ucdavis.edu


Qualifications

1989 Ph.D., Univ of Texas Southwestern Med Center, Immunology

1984 B.S., Rutgers University, Biology


Publications (selected)

  1. Murphy WJ, Back TC, Conlon KC, Komschlies KL, Ortaldo JR, Sayers TJ, Wiltrout RH, Longo DL. Antitumor effects of interleukin-7 and adoptive immunotherapy on human colon carcinoma xenografts. J Clin Invest 92: 1918-24, 1993.
  2. Funakoshi S, Taub DD, Anver MR, Raziuddin A, Asai O, Reddy V, Rager H, Fanslow WC, Longo DL, Murphy WJ Immunologic and hematopoietic effects of CD40 stimulation after syngeneic bone marrow transplantation in mice. Clin Invest 99:484, 1997.
  3. Sun K, Welniak LA, Panoskaltsis-Mortari A, O'Shaughnessy MJ, Liu H, Barao I, Riordan W, Sitcheran R, Wysocki C, Serody JS, Blazar BR, Sayers TJ, Murphy WJ. Inhibition of acute graft-versus-host disease with retention of graft-versus-tumor effects by the proteasome inhibitor bortezomib. Proc Natl Acad Sci U S A, 101(21): 8120-5, 2004.
  4. Sun K, Wilkins DE, Anver MR, Sayers TJ, Panoskaltsis-Mortari A, Blazar BR, Welniak LA, Murphy WJ. Differential effects of proteasome inhibition by bortezomib on murine acute graft-versus-host disease (GVHD): delayed administration of bortezomib results in increased GVHD-dependent gastrointestinal toxicity. Blood, 106(9): 3293-9.2005.
  5. Barao I, Hanash AM, Hallett W, Welniak LA, Sun K, Redelman D, Blazar BR, Levy RB, Murphy WJ. Suppression of natural killer cell-mediated bone marrow cell rejection by CD4+CD25+ regulatory T cells. Proc Natl Acad Sci U S A, 103(14): 5460-5, 2006.
  6. Berner V, Liu H, Zhou Q, Alderson KL, Sun K, Weiss JM, Back TC, Longo DL, Blazar BR, Wiltrout RH, Welniak LA, Redelman D, and Murphy WJ. IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat. Med., 13: 354-60, 2007.
  7. Alderson KL, Zhou Q, Berner V, Wilkins DE, Weiss JM, Blazar BR, Welniak LA, Wiltrout RH, Redelman D, Murphy WJ.Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy. J Immunol, 180(5): 2981-8, 2008.
  8. Hallett W, Ames E, Motarjemi M, Barao I, Shanker A, Tamang DL, Sayers TJ, Hudig D, Murphy WJ. Combination therapy using IL-2 and anti-CD 25 results in augmented natural killer cell-mediated antitumor responses. Biol Blood Marrow Transplant, 14(10): 1088-99, 2008.
  9. Zhou Q, Munger ME, Highfill SL, Tolar J, Weigel BJ, Riddle M, Sharpe AH, Vallera DA, Azuma M, Levine BL, June CH, Murphy WJ, Munn DH, Blazar BR. Program death-1 (PD-1) signaling and regulatory T cells (Tregs) collaborate to resist the function of adoptively transferred cytotoxic T lymphocytes (CTLs) in advanced acute myeloid leukemia (AML).Blood: 49-63, 2010.
  10. Urbieta M, Barao I, Jones M, Jurecic R, Panoskaltsis-Mortari A, Blazar BR, Murphy WJ, Levy RB. Hematopoietic progenitor cell regulation by CD4+CD25+ T cells. Blood, 115(23): 4934-43, 2010.
  11. Hu B, He Y, Wu Y, Bao G, Liu H, Welniak LA, Murphy WJ. Activated allogeneic NK cells as suppressors of alloreactive responses. Biol Blood Marrow Transplant, 16(6): 772-81, 2010.
  12. Orr MT, Murphy WJ, Lanier LL. 'Unlicensed' natural killer cells dominate the response to cytomegalovirus infection. Nat Immunol, 11(4): 321-7, 2010.
  13. Weiss JM, Ridnour LA, Back T, Hussain SP, He P, Maciag AE, Keefer LK, Murphy WJ, Harris CC, Wink DA, Wiltrout RH. Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J Exp Med, 207(11): 2455-67, 2010.
  14. Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ, Azuma M, Anderson AC, Kuchroo VK, Blazar BR. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood, 117(17): 4501-10, 2011.
  15. Barao I, Alvarez M, Ames E, Orr MT, Stefanski HE, Blazar BR, Lanier LL, Anderson SK, Redelman D, Murphy WJ.Mouse Ly49G2+ NK cells dominate early responses during both immune reconstitution and activation independent of MHC. Blood: 4501-10, 2011.
  16. Coghill JM, Sarantopoulos S, Moran TP, Murphy WJ, Blazar BR, Serody JS. Effector CD4+ T cells, the cytokines the generate, and GVHD: something old and something new. Blood, 117(12): 3268-76, 2011.
  17. Barao I, Alvarez, M, Redelman D , Weiss JM, Ortaldo JR , Wiltrout RH, and Murphy WJ. Hydrodynamic delivery of human IL-15 cDNA increases murine natural killer cell recovery after syngeneic bone marrow transplantation. Biol Blood Marrow Transplant 17, 1754-1764 (2011).
  18. Srinivasan M, Flynn R, Price A, Ranger A, Browning JL, Taylor PA, Ritz J, Antin JH, Murphy WJ, Luznik L, Shlomchik MJ, Panoskaltsis-Mortari A, Blazar BR. Donor B-cell alloantibody deposition and germinal center formation are required for the development of murine chronic GVHD and bronchiolitis obliterans. Blood 119, 1570-1580 (2012).
  19. Sun, K., Alvarez, M., Ames, E., Barao, I., Chen, M., Longo, DL, Redelman, D., Murphy, WJ. Mouse NK cell-mediated rejection of bone marrow allografts exhibits patterns consistent with Ly49 subset licensing. Blood 119, 1590-1598(2012).

Profile Details

NULL

Free SCIRP Newsletters
Copyright © 2006-2024 Scientific Research Publishing Inc. All Rights Reserved.
Top